.jpg)
Mood Disorders and Metabolic Inflammatory Illness:
What Does the Clinician Need to Know
Date: February 24, 2016
Location: Toronto, Ontario, Canada
This archived, self-directed learning activity is available for personal viewing and is based on the live event held in Toronto, Ontario on February, 24, 2016. The program involved a multidisciplinary faculty of clinician researchers from McMaster and the University of Toronto. The overarching aim of this learning activity was to provide clinicians with:
-
An update on the clinical overlap of diabetes, obesity and inflammatory disorders in adults with mood disorders with an emphasis on pathogenetic overlap and mechanistic models.
-
An evidence-based update and best practices in management of adults with mood disorders who have diabetes, obesity and/or inflammatory conditions.
-
A detailed review of the role of novel anti-inflammatory and metabolic treatments to improve cognitive function and mood symptom severity in adults with mood disorders
The Panel
Roger McIntyre, MD, FRCPC
Professor of Psychiatry and Pharmacology
Executive Director, BCDF
Head, Mood Disorders Psychopharmacology Unit
University of Toronto
Rebecca Anglin, MD, PhD, FRCPC
Assistant Professor,
Department of Psychiatry & Behavioural Neurosciences
Division of Gastroenterology
McMaster University
Julie Lovshin, MD
Lunenfeld-Tanenbaum Institute,
Mount Sinai Hospital,
Division of Endocrinology and Metabolism
University of Toronto
Sanjeev Sockalingam, MD, MHPE, FRCPC
Associate Professor of Psychiatry
University of Toronto
Deputy Psychiatrist-in-Chief (TGH & PMH)
Director, TWH Bariatric Surgery Psychosocial Program
UHN Centre for Mental Health
Rodrigo B. Mansur, MD
Clinical/Research Fellow in Psychiatry
University of Toronto
Mood Disorders Psychopharmacology Unit
UHN, Toronto General